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Abstract
Introduction: Environmental exposure to mites and fungi 
has been proposed to critically contribute to the develop-
ment of IgE-mediated asthma. A common denominator of 
such organisms is chitin. Human chitinases have been re-
ported to be upregulated by interleukin-13 secreted in the 
context of Th2-type immune responses and to induce asth-
ma. We assessed whether chitin-containing components in-
duced chitinases in an innate immune-dependent way and 
whether this results in bronchial hyperresponsiveness. Ma-
terials and Methods: Monocyte/macrophage cell lines were 
stimulated with chitin-containing or bacterial components 
in vitro. Chitinase activity in the supernatant and the expres-
sion of the chitotriosidase gene were measured by enzyme 
assay and quantitative PCR, respectively. Non-sensitized 
mice were stimulated with chitin-containing components 
intranasally, and a chitinase inhibitor was administered in-
traperitoneally. As markers for inflammation leukocytes 
were counted in the bronchoalveolar lavage (BAL) fluid, and 
airway hyperresponsiveness was assessed via methacholine 
challenge. Results: We found both whole chitin-containing 
dust mites as well as the fungal cell wall component zymo-
san A but not endotoxin-induced chitinase activity and chi-
totriosidase gene expression in vitro. The intranasal applica-
tion of zymosan A into mice led to the induction of chitinase 
activity in the BAL fluid and to bronchial hyperresponsive-
ness, which could be reduced by applying the chitinase in-
hibitor allosamidin. Discussion: We propose that environ-
mental exposure to mites and fungi leads to the induction of 
chitinase, which in turn favors the development of bronchial 
hyperreactivity in an IgE-independent manner.
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Introduction
Asthma is one of the most common chronic diseases 
in children and adolescents [1] and is characterized by 
reversible airway obstruction, inflammation, and airway 
hyperreactivity. The majority of asthma patients in this 
age-group show signs of the so-called T2 type of asthma: 
a phenotype that is characterized by the enhanced pro-
duction of T-helper cell type 2 cytokines, interleukin (IL)-
4, IL-5, and IL-13 and elevated concentrations of serum 
IgE as hallmarks of allergic asthma [2]. In this line, major 
risk factors for asthma in children are the general pres-
ence of atopy in the family or the child [3] and, more spe-
cifically, their early sensitization to house dust mites 
(HDMs) [4, 5]. Particularly in atopic asthmatics, there is 
a clear association with the indoor climatic quality as a 
marker for exposure to indoor allergens, environmental 
tobacco smoke, and disease [6].
However, this link seems not to be solemnly depen-
dent on IgE or allergic sensitization since a relationship 
between exposure to domestic allergens and bronchial 
hyperresponsiveness has also been described in adult 
atopic asthma patients who were only sensitized to aller-
gens other than HDMs or other indoor allergens [7]. Sup-
portive of this, atopic children (sensitized to indoor and/
or outdoor allergens, but not to fungi) exposed to high 
concentrations of molds in school and children living in 
desert environments with little or no mite allergen expo-
sure suffered from asthma symptoms or asthma worsen-
ing after exposure to fungi, which was most likely caused 
by a direct, non-IgE-mediated interaction [8, 9]. This may 
also explain why in the MAS study, a multicentre birth 
cohort exploring the natural development of allergies and 
asthma, no correlation between HDM levels and atopy or 
childhood asthma was found [4]. This also suggests that 
a different pathway besides IgE-mediated allergic sensiti-
zation may play a role in asthma development.
A possible candidate for this second pathway is chitin. 
Chitin is a common carbohydrate found in mites and fun-
gi, but not in mammalians. Chitin particles are recog-
nized by the immune system via receptors of the innate 
immunity [10] and thus induce the expression of chitin-
ases as effector molecules for defense in plants, fish, and 
insects. An antiparasitic role of human chitinases has not 
yet been described [11], but a role that chitinases may play 
in asthma seems likely. Acidic mammalian chitinase 
(AMCase), an endogenous lung chitinase induced by IL-
13, has been reported as a pivotal factor in the pathogen-
esis of (experimental) allergic asthma, whereas inhibition 
of AMCase activity suppressed this inflammatory process 
[12, 13]. In humans, 2 chitinases with chitin-cleaving ac-
tivity have been described: AMCase and chitotriosidase. 
AMCase activity was found to be elevated in the lung tis-
sues of asthmatic patients, and the expression of specific 
AMCase polymorphisms was associated with bronchial 
asthma in children [14]. Further, increased serum chito-
triosidase activity was observed in children and adults 
with asthma [15]. The chitinase-like protein YKL-40, 
which lacks chitin-cleavage activity, has been found ele-
vated in the plasma of asthma patients at levels correlat-
ing with the lung function [16, 17]. To further examine 
the role of chitinase in the development of asthma, we 
investigated whether mammalian chitinase can be in-
duced via the stimulation of TLRs, the principal pattern 
recognition receptors of the innate immune system, and 
whether this chitinase induction will enhance inflamma-
tion and bronchial hyperreactivity independent of IgE.
Materials and Methods
Cell Lines
Human monocyte cell line (THP-1) and mouse monocyte and 
macrophage cell line (RAW 264.7) were purchased from the Euro-
pean Collection of Cell Cultures (ECACC) in the UK and grown 
in RPMI 1640 or DMEM (Gibco BRL) supplemented with 10% 
low-endotoxin FBS (Hyclone) and 1% of an antibiotic-antimycot-
ic solution (Gibco BRL). Human monocyte-macrophages were 
isolated from the fresh buffy coats of healthy volunteers using a 
Ficoll-Paque gradient (Amersham Biosciences AB, Uppsala, Swe-
den) and grown in RPMI 1640 supplemented with 10% low-endo-
toxin FBS and 1% of an antibiotic-antimycotic solution.
Cell Stimulation and Total RNA Extraction
Cells grew in 6-well plates at 37°C with 5% CO2 until they were 
80% confluent. The cells were stimulated in a serum-free medium 
for 6 h with LPS 100 ng/mL (Escherichia coli K12, List Biological 
Laboratories, Campbell, CA, USA), zymosan A (Saccharomyces 
cerevisiae) 250 μg/mL (Molecular Probes, Eugene, OR, USA) or 
Dermatophagoides pteronissinus (Der. p.) 100 μg/mL (Allergon 
AB, Aengelholm, Sweden). To investigate the receptor pathway, 
we added 2 μg/mL monoclonal antibodies against dectin-1 (R&D, 
UK), anti-TLR-2 (eBioscience, USA), or anti-CD 205 (mannose 
receptor) (BD Bioscience, Switzerland). The supernatant was tak-
en and immediately frozen at −20°C. The QIAmp RNA Blood 
Mini Kit (Qiagen) supplemented with RNase-free DNase (Qiagen) 
was used for a total RNA isolation.
RT-PCR and Quantitative PCR (TaqMan®) of In Vitro 
Material
We performed reverse transcription with 300 ng of total RNA 
in a final volume of 30 µL using the reverse transcription reagents 
of Applied Biosystems (Forster City, CA, USA). The quantitative 
real-time PCR was carried out in an ABI Prism 7700 Sequence De-
tection SystemTM (Applied Biosystems). To detect the gene for 18S 
rRNA, we used the primers with the sequence 5′-AGTCCCT-
Chitinase-Induced Nonallergic Asthma in 
Mice
565Int Arch Allergy Immunol 2021;182:563–570
DOI: 10.1159/000513296
GCCCTTTGTACACA-3′ (200 mM) and 5′-GATCCGAGGGCC-
TCACTAAAC-3′ (200 mM). The probe had the sequence 
5′-CGCCCGTCGCTACTACCGATTGG-3′ (250 mM). To mea-
sure the expression of the human chitotriosidase gene (Hs 
00185753_m1), of the human AMCase gene (Hs 00757767_m1) 
and of the mouse chitotriosidase gene (Mm 01291362_m1), we 
used pre-developed assays (Applied Biosystems). The quantitative 
real-time PCR was performed with 3 μL of the reverse transcrip-
tion solution in a final volume of 25 μL. We added an adequate 
amount of primers and probes, together with 12.5 µL TaqMan 
Universal PCR Master MixTM (Applied Biosystems). We normal-
ized the determined gene expression values to the parallel mea-
sured endogenous control 18S rRNA and analyzed the data with 
the comparative (∆∆Ct) method according to the manufacturer’s 
instructions (Applied Biosystems).
Animals
Female BALB/c mice, 6–8 weeks old, were purchased from the 
Harlan-Winkelmann GmbH, Borchen, Germany. The animals 
were certified as pathogen and virus-free according to the supplier: 
the mice were kept under pathogen-free conditions and main-
tained a standard diet and water ad libitum. The animal Ethics 
Committee (Ethik Kommission der Charité Universitätsmedizin 
Berlin) approved all experimental procedures.
The mice were anesthetized with isoflurane and intranasally 
challenged daily with 100 μg (4 mg/mL) zymosan A in PBS or 25 
μL PBS for 5 days. Four hours before the intranasal challenge, the 
mice had an intraperitoneal application of 30 μg of the chitinase 
inhibitor allosamidin (Industrial Research, New Zealand) or PBS.
On day 5, 24 h after the last intranasal stimulation, in vivo lung 
function to inhaled methacholine (MCh; Sigma, St Louis, MO, 
USA) was measured by whole-body plethysmography (WBP; 
EMKA Technologies, Paris, France), as previously reported [18]. 
Each mouse was placed briefly in the main chamber of a body ple-
thysmograph. Aerosolized PBS (baseline) and MCh in increasing 
concentrations (6–50 mg/mL) were nebulized ultrasonically 
through an inlet of the main chamber for 3 min. Pressure differ-
ences between the main and the reference chamber caused by vol-
ume and resultant pressure changes during the mouse’s inspira-
tion and expiration were measured and averaged for 3 min after 
each nebulization. Enhanced pause (Penh) values were calculated 
as an index of airway obstruction.
On day 5, mice were assessed for airway inflammation. Lungs 
were lavaged twice via a tracheal tube with 0.8 mL of cold PBS (Se-
romed, Biochrom, Berlin, Germany) supplemented with protease 
inhibitor cocktail tablets (Cat. No. 11 836 153 001, complete mini, 
Roche, Penzberg, Germany). Cells were counted, and cytospin 
slides were stained with Diff Quick (Dade Behring AG, Düdingen, 
Switzerland). Bronchoalveolar lavage (BAL) cells were differenti-
ated according to morphological criteria by counting at least 100 
cells using standard hematological procedures under light micros-
copy. The cell-free BAL fluid of the first lavage was stored at −70°C 
until the cytokine assay.
Enzyme Assays in vivo and in vitro
Chitinase enzyme activity was determined with fluorogenic 
substrate 4-methylumbelliferyl-β-D-N,N′,N′′-triacetylchitotrio-
side (Sigma M-5639) as previously described [19]. Then 50 μL of 
undiluted supernatant was incubated with 100 μL of a solution 
containing 22 μmol/L of the artificial substrate 4-methylumbelliferyl-
β-D-N,N′,N′′-triacetylchitotrioside (Sigma M-5639) in a 0.5 mol/L 
citrate phosphate buffer with a pH of 5.2 for 15 min at 37°C. The 
reaction was stopped by using 3 mL of Na2CO3 100 mM and 10.6 
g/L H2O. The fluorescent 4-methylumbelliferone was measured 
with a fluorimeter (Perkin-Elmer Corp., Norwalk, CT, USA) at 455 
nm.
Statistical Analysis
Values for all measurements were expressed as mean ± stan-
dard error of the mean. Pairs of groups were compared using the 
Mann-Whitney U test. Significance was set at a p value of ≤0.05.
Results
HDMs and Fungal Components Induce Expression of 
Chitinases in vitro
We investigated whether stimulation with chitin-con-
taining pathogens, fungi, and mites via TLR could induce 
the expression of chitinase in a monocyte/macrophage 
cell line. Zymosan A of S. cerevisiae (fungi), a TLR-2 li-
gand, as well as whole-HDMs (Dermatophagoides ptero-
nyssinus [Der. p.]) enhanced chitinase activity in the cell-
free supernatant from the human monocyte cell line 
THP-1 shown in Figure 1a. We measured an 8-fold in-
crease in chitinase activity after stimulation with zymo-
san A in relation to non-stimulated cells. The chitinase 
activity after stimulation with Der. p. was 50-fold higher 
than the control. These results were confirmed in blood-
derived monocyte macrophages of human donors and in 
the mouse monocyte-macrophage cell line RAW 264.7 
(data not shown). Zymosan A and HDMs also induced 
the expression of the chitotriosidase gene in THP-1 
shown in Figure 1b. The expression of the AMCase gene 
was not detectable. Similarly, zymosan A and Der. p. in-
duced the expression of the chitotriosidase gene in the 
mouse macrophage cell line RAW 264.7 and human 
blood-derived human monocyte-macrophages (data not 
shown). Stimulation with the bacterial cell wall compo-
nent LPS, a ligand for TLR4, showed no chitinase induc-
tion (enzyme activity and gene expression).
Inhibition of Dectin-1, TLR-2, or Mannose Receptor 
Decreased Chitinase Activity in vitro
Since TLR-2 and dectin-1, a transmembrane recep-
tor that binds to yeast components, have been described 
to be involved in zymosan A and chitin recognition [10, 
20, 21], we investigated whether this is also true for the 
expression of chitinases in response to zymosan A. 
Therefore, we incubated THP-1 cells with blocking an-
tibodies against TLR-2, dectin-1, or the mannose recep-
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tor CD206, which recognizes a number of microbial 
proteoglycans, such as zymosan A. The expression of 
the chitinase gene was significantly inhibited after the 
addition of anti-dectin-1, anti-CD206, and to a lesser 
extent, with the anti-TLR-2 antibodies, as shown in Fig-
ure 2.
Airway Stimulation of Nonallergic Mice with Chitin-
Containing Components Induced Chitinase in BAL, 
Bronchial Hyperreactivity, and Inflammation
We investigated whether the application of chitin-
containing components to mice induced chitinase activ-
ity in the lung tissue and whether this was associated with 
bronchial hyperreactivity and inflammation. After the 
daily application of zymosan A via intratracheal applica-
tion to female BALB/c mice for 5 days, the activity of the 
chitinase enzyme in the BAL fluid was increased 2-fold in 
comparison to placebo-treated animals, as shown in Fig-
ure 3. The number of inflammatory cells in the BAL fluid 
and airway hyperreactivity increased as well, as shown in 
Figure 4. In comparison to the PBS control group, there 
was a significant increase in leucocytes harvested from 
BAL when zymosan A was administered. The BAL fluid 
demonstrated a higher number of lymphocytes, neutro-
phils, and eosinophils compared to the PBS control. This 





















































Fig. 1. Elevated chitinase activity after mite or fungi stimulation. Increased chitinase enzyme activity in superna-
tant (a) and increased chitotriosidase gene expression in THP-1 cells after stimulation with Dermatophagoides 
pteronyssinus or zymosan (b). No significant difference after LPS stimulation. Data are mean ± SEM, n = 3.
Table 1. White cell count and differentiation in BAL of nonallergic mice
Cell type Negative control (n = 3) Zymosan (n = 3) Zymosan and allosamidin (n = 7)
103 cells/mL % 103 cells/mL % 103 cells/mL %
Lymphocytes 0±0 0 49±17 6 18±6 3
Neutrophiles 2±1 2 646±101 84 460±113 87
Eosinophiles 0±0 0 22±14 3 9±4 2
Macrophages 40±23 98 57±28 7 44±15 8
BAL, bronchoalveolar lavage.
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Amelioration of Airway Inflammation and 
Hyperreactivity after Chitinase Neutralization
To further investigate whether the chitinase pathway 
induced by zymosan A was crucial in the induction of 
nonallergic airway inflammation in mice, we blocked it 
with a daily intraperitoneal application of the chitinase 
inhibitor, allosamidin 4 h prior to the intranasal challenge 
of zymosan A. This chitinase inhibition resulted in the 
inhibition of chitinase enzyme levels (Fig. 3) and the cel-
lular infiltration in the BAL fluid when compared to 
Balb/c mice intranasally treated with zymosan A, as 
shown in Figure 4.
In vivo lung functionality in response to MCh was im-
proved in mice treated with zymosan A after chitinase 
inhibition, when compared with mice only treated with 
zymosan A, as shown in Figure 4. Furthermore, the per-
centage of lymphocytes and eosinophils was reduced in 
the BAL fluid after additional application of allosamidin 
to zymosan A, as shown in Table 1.
Discussion/Conclusion
We show here the first description of a model for an 
allergen-independent specific enhancement of airway in-
flammation and hyperreactivity by chitin. Our results 
show that chitin, a molecule contained in fungi and mites, 
is able to induce an increased expression of chitinase in 












































































































p = 0.026p = 0.017
Fig. 2. Decreased gene expression of chitotriosidase mRNA was 
measured after stimulation of THP-1 cells with zymosan and in-
hibitory antibodies for Dec 206 (a), TLR-2 (b), or dectin-1 recep-
tors (c). After addition of Dec 205, SIGN, or SIGN-related receptor 
antibodies, there was no inhibition of chitinase gene expression 
detected. Data are SEM, n = 3. THP-1, human monocyte cell line.
Fig. 3. BALB/c mice showed a significant increase of chitinase ac-
tivity in BAL after daily intranasally stimulation with zymosan. 
After zymosan stimulation and daily intraperitoneal application of 
chitinase inhibitor allosamidin, we determined a decrease in en-
zyme activity. Data are mean ± SEM. BAL, bronchoalveolar lavage.
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tized murine lung cells. Mice treated with the chitinase-
inductor zymosan A showed elevated bronchial chitinase 
enzyme activity and displayed increased airway hyperre-
activity and airway inflammation, whereas neutralization 
with the chitinase inhibitor allosamidin inhibited this. 
This suggests that chitin-containing pathogens may cause 
a direct and IgE-independent innate immune response 
resulting in the lung damage.
Our data suggest that ubiquitous environmental fac-
tors, such as mites or fungi can lead to airway inflamma-
tion and airway hyperreactivity independent of an aller-
gic or IgE-mediated pathway. This may explain why ex-
posure to these components can enhance the development 
of asthmatic symptoms without the requirement of spe-
cific sensitization [9, 22].
Our data might help to better understand the seem-
ingly paradoxical observation in the Manchester Allergy 
and Asthma Study (MAAS), namely, that children in the 
allergen avoidance group with lower exposure to HDMs 
developed similar levels of specific sensitization, but sig-
nificantly less asthma-like symptoms [23].
In the past, it was believed that mite exposure might be 
directly associated with the development of asthma. Ex-
posure to fungi was proposed as one possible factor ex-
plaining this high asthma risk [8]. Our data now broaden 
this suggestion by showing that exposure to components 
that induce chitinase can induce airway inflammation 
and hyperreactivity. This conclusion aligns well with 
available epidemiological data: a worldwide study in 146 
centers investigating climate and prevalence of asthma 
symptoms in children showed a close correlation of air-
way obstruction to increased indoor relative humidity 
and temperature [24], the former influencing the HDM 
infestation in homes [25]. Other factors influenced by the 
level of indoor relative humidity are home dampness and 
molds, both associated with the prevalence of asthma and 
bronchial hyperreactivity in several studies [25].
In a prospective cohort study, the German Multicenter 
Allergy Study showed that children not only developed 
significantly less sensitization [4] but also had significant-
ly fewer coughing episodes at night when effective HDM 
avoidance was established [26]. Likewise, significant re-
duction of HDM exposure in a longitudinal study in 
Manchester (MAAS) resulted in decreased lung symp-
toms at the age of 1 year [27] and significantly lower air-
way resistance at 3 years of age compared to the group 
with normal HDM exposure [28].
Our data suggest that chitin-containing pathogens 
such as fungi and mites may directly induce an inflamma-





















































PBS in (n = 4)
Zymosan in/PBS ip (n = 8)
Zymosan in/Allosamidin ip (n = 8)
Fig. 4. Increased airway hyperresponsiveness and inflammation 
after intranasal fungal stimulation. Airway hyperresponsiveness 
(a) and airway inflammation (b) shown as cells/mL in the BAL 
fluid of nonallergic BALB/c mice. Results after intranasal and in-
traperitoneal stimulation with PBS (a: n = 4, b: n = 3) as negative 
control, intranasal stimulation with zymosan with intraperitone- 
al PBS (a: n = 8, b: n = 7) or the chitinase inhibitor allosamidin 
(a: n = 8, b: n = 7). An increase of airway inflammation and hyper-
responsiveness after chitin-containing zymosan and a downward 
trend after intraperitoneal chitinase inhibition could be shown. 
Data are mean ± SEM. BAL, bronchoalveolar lavage.
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ciation between mammalian chitinase and bronchial 
asthma has been reported before [16].
Lee et al. [29] elegantly demonstrated in vitro that the chi-
tinase-like molecule, Chi3l1, binds to the IL-13-receptor α2 
and mediates biological responses, including the regulation 
of cellular apoptosis, oxidative tissue injury, and airway in-
flammation, thus linking this molecule with Th2-mediated 
allergic immune responses. Accordingly, serum levels of the 
chitinase-like protein YKL-40 showed significant correla-
tions with the baseline lung function and were increased in 
children with a significant response in either the exercise 
challenge or the bronchodilator test [30]. Consequently, 
strategies to inhibit the induction of airway inflammation by 
blocking of chitinases would include attempts to obstruct up-
stream IL-13 production. Our data support the concept that 
chitinases induce host anti-parasite immune responses and 
that airway inflammation in asthma is enhanced by this path-
way in a parasite-independent nonallergic way [31].
Environmental exposure to organisms such as fungi and 
mites directly induce chitinases and bronchial hyperrespon-
siveness, and we interpret it as a representation of an innate 
immune response to common molecular patterns associat-
ed with such organisms. Chitin has been shown to be a 
strong activator of the alternative complement pathway and 
thereby shapes the ensuing immune response upon inhala-
tion [32]. Thus, we propose that the induction of chitinases 
contributes to asthma not only as a secondary enhancer of 
ongoing allergic airway inflammation but as a pivotal ele-
ment in the initiation of bronchial hyperreactivity and asth-
ma independent of an allergen-induced T2-type inflamma-
tion. Consequently, approaches to inhibiting the induction 
of airway inflammation and bronchial hyperreactivity would 
require effective measures for reducing the environmental 
exposure to organisms such as fungi and mites. Future stud-
ies have to prove whether this strategy will translate into a 
reduced risk for asthma development in children.
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